Assessment and control of Fc functionality during biotherapeutic antibody development and manufacturing is essential as receptor binding is linked to the safety and efficacy of the final drug. Typically, cell-based assays (such as ADCC, ADCP, and CDC) and/or surrogate binding assays are used for routine monitoring or characterization of the Fc functionality. The use of Biacore ligand-binding as...